Cell Source Inc Stock OTC Bulletin Board
Equities
US15114L1044
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
03-22 | Cell Source, Inc. announced that it has received $4.76017 million in funding | CI |
2023 | Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Sales 2021 | - | Sales 2022 | - | Capitalization | 29.96M 40.78M |
---|---|---|---|---|---|
Net income 2021 | -5M -6.8M | Net income 2022 | -5M -6.8M | EV / Sales 2021 | - |
Net Debt 2021 | 6.4M 8.72M | Net Debt 2022 | 7.68M 10.45M | EV / Sales 2022 | - |
P/E ratio 2021 |
-6.58
x | P/E ratio 2022 |
-4.68
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 70.08% |
Managers | Title | Age | Since |
---|---|---|---|
Itamar Shimrat
CEO | Chief Executive Officer | 63 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Dennis Brown
CHM | Chairman | 74 | 14-06-29 |
Itamar Shimrat
CEO | Chief Executive Officer | 63 | - |
Darlene Soave
BRD | Director/Board Member | 80 | 21-03-24 |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |